S Afr Med J. 1998 Sep;88(9 Pt 2):1133-55.
This Guideline targets chronic heart failure (CHF) due to left ventricular systolic dysfunction. The approach to both diagnosis and management of the CHF syndrome is included in this document. Although the aetiology of the heart failure may differ among the different racial groups (hypertension, end-stage rheumatic heart disease and idiopathic cardiomyopathy in black patients, and ischaemic heart disease in white, coloured and Indian patients), the end result is a dysfunctional left ventricle. The therapy applied is therefore applicable to a wide spectrum of CHF patients. This allows for the compilation of a CHF Guideline that is relevant to a large group of patients. All health care workers are targeted in this Guideline, although the general practitioner and specialist physician would probably gain the most from it. The clinical recognition of heart failure as well as its management is a difficult clinical problem and a primary care guideline will have to be a separate document, although the summary of this Guideline can be appreciated at a primary level of care. The motivation for the development of this guideline includes: Congestive heart failure is probably the most important cardiovascular condition that is still increasing in incidence and prevalence. A major problem is the clinical recognition of the heart failure syndrome, and this Guideline concentrates on outlining a practical approach to obtaining a history and doing a relevant examination. Unless the condition is correctly diagnosed, any recommendations on therapy lose their relevance. Numerous large, randomised, international, double-blind randomised trials are a feature of this condition and a Guideline giving clear recommendations for therapy based on these trials is crucial. The ordinary busy practitioner cannot be expected to read all these published studies and assimilate them into a coherent protocol of management. South Africa has not published a guideline on CHF that sets the standard of care that is considered acceptable. With the emergence of essential drug lists, managed health care groups and a more litigious society in South Africa, this Guideline will serve as the standard for the optimal management of CHF.
Improvement in the quality of life, reduced CHF hospitalisations and mortality were the major considerations in the development of this Guideline. No economic analysis was made to assess cost-effective therapy, as this was not the brief of this document. The Directorate Medical Schemes, Supplies and Pharmaceutical Services (EDL) was a member of the working group.
All the data were gathered from the published literature. Preference was given to the evidence provided by the numerous, large randomised CHF trials, the respective heart failure guidelines published by the European Society of Cardiology and the ACC/AHA Task Force and the clinical practice guidelines published by the US Department of Health and Human Services. An expert panel was then assembled and changes were made to the draft guideline both at a convened meeting and later on the basis of written comments following the distribution of a second draft. Where the evidence available was inconclusive or non-existent, a consensus of expert opinion was obtained. The most recent publications considered were published in 1997, but the literature was scanned on an ongoing basis for new data that may have changed the recommendations. METHODOLOGY/SPONSORSHIP: See Annexure B, p. 1155.
A clear history should be obtained identifying the symptoms of the heart failure syndrome together with an attempt at identifying an aetiology and precipitating factor(s) underlying the syndrome. Clinical examination is emphasised, including identifying the three tenets of the clinical diagnosis of CHF (syndrome, aetiology, precipitating factor(s)). The CXR, ECG (resting, effort), selected blood tests are recommended as a routine in the diagnosis of CHF. Echocardiograph
本指南针对因左心室收缩功能障碍引起的慢性心力衰竭(CHF)。本文档涵盖了CHF综合征的诊断和管理方法。尽管不同种族群体中心力衰竭的病因可能有所不同(黑人患者中为高血压、终末期风湿性心脏病和特发性心肌病,白种人、有色人种和印度患者中为缺血性心脏病),但最终结果都是左心室功能失调。因此所应用的治疗方法适用于广泛的CHF患者。这使得能够编写一份与大量患者相关的CHF指南。本指南针对所有医护人员,不过全科医生和专科医生可能从中获益最多。心力衰竭的临床识别及其管理是一个棘手的临床问题,尽管本指南的总结在初级护理层面也能理解,但初级护理指南将不得不单独成册。制定本指南的动机包括:充血性心力衰竭可能是发病率和患病率仍在上升的最重要的心血管疾病。一个主要问题是心力衰竭综合征的临床识别,本指南着重概述获取病史和进行相关检查的实用方法。除非病情得到正确诊断,否则任何治疗建议都将失去相关性。众多大型、随机、国际、双盲随机试验是这种疾病的特点,基于这些试验给出明确治疗建议的指南至关重要。不能期望忙碌的普通从业者阅读所有这些已发表的研究并将其融入连贯的管理方案。南非尚未发布设定可接受治疗标准的CHF指南。随着基本药物清单、管理式医疗集团的出现以及南非社会诉讼增多,本指南将作为CHF最佳管理的标准。
生活质量的改善、CHF住院率的降低和死亡率是制定本指南时的主要考虑因素。未进行经济分析以评估成本效益疗法,因为这不是本文档的任务。医疗计划、供应和制药服务局(EDL)是工作组的成员。
所有数据均从已发表的文献中收集。优先选用众多大型CHF随机试验、欧洲心脏病学会和美国心脏病学会/美国心脏协会工作组各自发布的心力衰竭指南以及美国卫生与公众服务部发布的临床实践指南所提供的证据。随后组建了一个专家小组,在一次召集会议上以及后来根据第二稿分发后的书面意见对指南草案进行了修改。在现有证据不确定或不存在的情况下,达成了专家意见共识。考虑的最新出版物发表于1997年,但持续扫描文献以获取可能改变建议的新数据。方法/资助:见附件B,第1155页。
应获取清晰的病史,识别心力衰竭综合征的症状,并尝试确定该综合征的病因和促发因素。强调临床检查,包括识别CHF临床诊断的三个要点(综合征、病因、促发因素)。建议将胸部X线、心电图(静息、运动)、选定的血液检查作为CHF诊断的常规检查。超声心动图